IDEXX Laboratories Financials - Benzinga

IDEXX Laboratories Inc

IDXXNASDAQ

Trade with Public

Trade with Public

$545.02

-11.67-2.1%

Dern. MÀJ: Sep 1, 1:43 PM

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Actionnariat Comparer Options Rapport sur les stocks

IDEXX Laboratories Financials

IDEXX Laboratories (IDXX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Why Is IDEXX Laboratories Stock Gaining Tuesday?

IDEXX Laboratories (IDXX) stock rose after reporting Q2 earnings of $4.27/share and $1.22B in revenue, beating Wall Street estimates.

Vandana Singh

PRO
IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 Est; Narrows FY2026 Sales Guidance from $4.675B-$4.760B to $4.700B-$4.745B vs $4.711B Est

IDEXX Laboratories (NASDAQ:IDXX) raises FY2026 GAAP EPS guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 analyst estimate. Narrows FY2026 sales outlook from $4.675 billion-$4.760 billion to $4.700 billion-$4.745

Benzinga Newsdesk

PRO
IDEXX Laboratories Q2 EPS $4.27 Beats $3.96 Estimate, Sales $1.217B Beat $1.201B Estimate

IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $4.27 per share which beat the analyst consensus estimate of $3.96 by 7.83 percent. This is a 17.63 percent increase over earnings of $3.63 per share from

Benzinga Newsdesk

Idexx Laboratories Raises Guidance On Higher Clinical Visits, Diagnostic Frequency

Idexx Laboratories shares edge higher as revenue tops estimates but earnings per share misses; guidance raised.

Vandana Singh

PRO
CORRECTION: IDEXX Laboratories Q1 EPS $3.47 Beats $3.41 Estimate, Sales $1.141B Beat $1.109B Estimate

IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $3.47 per share which beat the analyst consensus estimate of $3.41 by 1.76 percent. This is a 20.91 percent increase over earnings of $2.87 per share from

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved